Aims and objectives

The ESCMID Study Group for Respiratory Viruses (ESGREV) is at the forefront of respiratory virus research and medicine. Uniting experts on a global scale, we are committed to: 

  • Coordinating efforts to strengthen new and existing research and education initiatives through global collaboration
  • Establishing consensus on new scientific and recently published data, while addressing knowledge gaps
  • Leading the development of cross-organisational clinical guideline recommendations on diagnostic testing strategies, prevention, antiviral treatments, and vaccine development and deployment

Activities and resources

ESGREV Newsletter, Spring 2024, March 2024 

Download


ESGREV Newsletter, Spring 2023, March 2023 

Download


ESGREV Newsletter, Autum 2023, September 2023 

Download


ESGREV Newsletter, Winter 2023, December 2023

Download

American Society of Transplantation and Cellular Therapy series: #7 – Management of respiratory syncytial virus infections in hematopoietic cell transplant recipients. 

El Chaer F, Kaul DR, Englund JA, Boeckh M, Batista MV, Seo SK, Carpenter PA, Navarro D, Hirsch HH, Ison MG, Papanicolaou GA, Chemaly RF. Transplant Cell Ther. 2023;29(12):730–738.

Go to publication


Disease burden and inpatient management of children with acute respiratory viral infections during the pre-COVID era in Germany: a cost-of-illness study. (PrePrint)

Alchikh M, Conrad TOF, Obermeier PE, Ma X, Schweiger B, Opota O, Rath BA. Viruses. 2023110966. Preprint.

Go to publication


Epidemiology of respiratory viruses among children during the SARS-CoV-2 pandemic: A systematic review and meta-analysis. 

Dallmeyer L, Schuz ML, Fragkou PC, Omony J, Krumbein H, Dimopoulou D, Skevaki C. Int J Infect Dis. 2024;138:10–18.

Go to publication


Immune response to respiratory viruses and respiratory viral infections in susceptible populations. 

Fragkou PC, Dimopoulou D, De Angelis G, Menchienelli G, Chemaly RF, Skevaki C, On behalf of the European Society of Clinical Microbiology Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV). Front Med (Lausanne). 2023;10:1330265.

Go to publication


Clinical trials for treatment of respiratory viral infections in recipients of haematopoietic cell transplantation and cellular therapies: are we on the right path to the finish line? 

Sassine J, Hirsch HH, Chemaly RF. Clin Microbiol Infect. 2024;30(3):270–275.

Go to publication


An international multi-center study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with Obinutuzumab vs. Rituximab. 

Shafat T, Grupel D, Porges T, Abuhasira R, Belkin A, Deri O, Oster Y, Zahran S, Horwitz E, Horowitz NA, Khatib H, Batista MV, Cortez AC, Brosh‐Nissimov T, Segman Y, Ishay L, Cohen R, Atamna A, Spallone A, Chemaly RF, Ramos‐Ramos JC, Chowers M, Rogozin E, Oren NC, Keske S, Barchad OW, Nesher L, and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV). Cancer Medicine. 2024;13(3):e6997.

Go to publication

ESGREV/ESGEM: The use of saliva for surveillance of respiratory viruses

Go to webinar

Update on current emerging infection 

Post-graduate course 

Download


Update on infections in immunocompromised hosts 

Post-graduate course 

Download

Executive Committee

  Roy Chemaly

Roy Chemaly

Chairperson
University of Texas MD Anderson Cancer Center. Department of Infectious Disease, Infection Control & Employee Health
Houston, United States
  Chrysanthi Skevaki

Chrysanthi Skevaki

Secretary
Philipps University Marburg
Gießen, Germany
  Barbara Rath

Barbara Rath

Treasurer
Université Bourgogne-Franche Comté. UMC Chrono-Environnement
Besançon, France
  Sotirios Tsiodras

Sotirios Tsiodras

Science Officer
Attikon University Hospital. 4th Department of Internal Medicine
Athens, Greece
  Louis Bont

Louis Bont

Education Officer
UMC Utrecht
Utrecht, Netherlands

Contact

If you have questions or comments for our study group, we warmly invite you to contact us!

Contact form